← Eichor
Study identifier: NCT06140901 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Bronchial Epithelium of Children With Post-infectious Bronchiolitis Obliterans

Condition: Bronchiolitis Obliterans  ·  Sponsor: Institut National de la Santé Et de la Recherche Médicale, France

PhaseNA
Planned participants450
Who can joinAll sexes, 1 Month to 6 Years
Healthy volunteersNo

About this study

Bronchiolitis obliterans (BO) is an irreversible chronic obstructive pulmonary pathology leading to obstruction and/or obliteration of the small airways. In children, the most common form of BO occurs following a serious lower respiratory tract infection. This is a rare complication; the incidence is unknown. The diagnosis, often late, is made on clinical, spirometric and radiological arguments. The pathophysiology would be linked to damage to the airway epithelium. PIBO is most commonly associated with adenovirus (ADV) infection (serotypes 3, 7, 11 and 21) but also other viruses such as rhinovirus (RV). The treatment of PIBO is not clearly established, it remains empirical. The research hypothesis is that the morphology of the nasal epithelium of children with ADV or RV infection is different for those progressing to PIBO. The main objective of the proposed observational study is to characterize damage to the respiratory epithelium in these children. This is a single-center prospective longitudinal study (AP-HM), in children aged 1 month to 6 years, comparing children hospitalized for lower respiratory infection by ADV or RV progressing or not to PIBO. All children included will have a nasal swab and brushing on D0. Children developing PIBO will have nasal brushing with bronchial endoscopy with bronchial biopsies and bronchoalveolar washing at the time of PIBO diagnosis and again at M6 in case of partial response to treatment. This is therefore a pilot study aimed at defi…

This description comes directly from the study's public registry record.

Talk to the study team

Julie MAZENQ, PhD  ·  0491386808  ·  julie.mazenq@ap-hm.fr

Delphine Gras  ·  delphine.gras@univ-amu.fr

Always discuss trial participation with your own doctor first.

Locations (1)

APHMMarseille, FranceRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06140901